Eylea and Salivary gland cancer stage iii - from FDA reports
There is no Salivary gland cancer stage iii reported by people who take Eylea yet. This review analyzes which people have Salivary gland cancer stage iii with Eylea. It is created by eHealthMe based on reports from FDA, and is updated regularly.
What to expect?
Personalized health information
On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA since 1977. Our tools are simple to use, anonymous and free. Start now >>>
On Dec, 16, 2017
No report is found.
How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.
Subscribe to the study: get notified of updates to the study.
Do you have Salivary gland cancer stage iii when taking Eylea?
- Check symptoms - is salivary gland cancer stage iii caused by a drug or a condition?
- Get alerts to symptoms - forecast your symptoms and get alerts
- Report the side effect - help people in need and in real time
- Ask a question - ask a question related to the study
- write a review - share your experience related to the study
- More tools...
Expand the study to include all drugs with the same ingredientsSalivary gland cancer stage iii and drugs with ingredients of aflibercept.
Expand the study to include reports from both FDA and eHealthMeSalivary gland cancer stage iii and Eylea from FDA and eHealthMe reports
Eylea has active ingredients of aflibercept. It is often used in macular degeneration. (latest outcomes from Eylea 6,687 users)
Salivary Gland Cancer Stage Iii
Salivary gland cancer stage iii (salivary gland cancer larger than 4 cm across and/or is growing into nearby soft tissues) has been reported by people with factor viii deficiency, high blood pressure, multiple myeloma (latest reports from 2 Salivary gland cancer stage iii patients).